BPC-157 has become one of the most-cited peptides in regenerative and gastrointestinal research over the last decade. Most published work uses injectable administration in animal models — yet researchers increasingly ask the same question: can BPC-157 be studied in an oral, enteric-coated form, and what changes when it is? This guide walks through the formulation rationale for enteric-coated capsules, the research contexts where oral delivery is preferred, and how to evaluate supplier quality. It is not a therapeutic guide. All content is framed for in vitro and ex vivo research use only.
1. What makes an enteric-coated capsule different?
A standard immediate-release capsule dissolves in the stomach at pH 1.5–3.5 — an environment that degrades most peptides within minutes. An enteric coating is a pH-sensitive polymer shell (commonly methacrylic acid copolymers such as Eudragit L100 or cellulose acetate phthalate) designed to remain intact in gastric conditions and dissolve only once the capsule enters the small intestine at pH 5.5–7.0.
For a peptide like BPC-157, this matters for three reasons:
- Protection from pepsin. Gastric pepsin cleaves peptide bonds rapidly at low pH. Enteric coating defers release until the peptide has passed the stomach.
- Site-specific release. Dissolution occurs in the duodenum/jejunum, which is itself a tissue of interest for intestinal-barrier and gut-protection research.
- Reproducibility. In comparative research — for example, oral vs. injectable pharmacokinetic models — enteric coatings give a more predictable release window than uncoated oral formulations.
Importantly, BPC-157 is itself derived from a protein fragment originally described as part of human gastric juice. Published work often notes its stability in gastric secretions — one of the reasons it is studied as a candidate for oral research formulations at all.
2. Why researchers study oral BPC-157 specifically
Most animal studies of BPC-157 use intraperitoneal or subcutaneous administration because it produces consistent systemic exposure in small-mammal models. Oral research is a distinct line of investigation with its own questions:
2.1 Intestinal tissue protection models
When the tissue of interest is the intestinal epithelium itself — for example, in colitis, IBD, NSAID-induced enteropathy, or anastomotic healing research — oral delivery places the study compound directly in contact with the target tissue. Published literature on BPC-157 in these models frequently uses oral or intragastric routes for this reason.
2.2 Oral bioavailability characterization
Oral bioavailability of peptides is generally low due to gastric degradation and limited intestinal permeability. Enteric-coated capsules are one of the standard tools for separating formulation effects (protection + targeted release) from intrinsic peptide properties (permeability, metabolism). Comparative studies pairing enteric-coated capsules with the same peptide in parenteral form are a common experimental design.
2.3 Gut–brain and vagal signaling research
Some research examines whether orally delivered peptides can exert systemic or central-nervous-system effects via gut afferent signaling rather than plasma absorption. Enteric-coated oral peptides are a reasonable tool for this design, as release at the small-intestinal level aligns with the anatomy of vagal afferents.
2.4 Formulation stability and logistics
Enteric-coated capsules in a sealed bottle are stable at room temperature for extended periods, eliminating the cold-chain and reconstitution steps required for lyophilized injectable peptides. For long-running research projects, this is a meaningful operational difference.
3. What to look for in a research-grade supplier
The single most common failure point in peptide research is not the peptide — it is the gap between what is printed on the label and what is actually in the vial. A credible oral BPC-157 product should provide each of the following:
- Third-party Certificate of Analysis per batch. Purity ≥98% measured by HPLC, identity confirmed by ESI-MS, endotoxin per USP <85>, bioburden per USP <61>. The COA should come from an independent analytical laboratory (e.g., Analytical Sciences International, Eurofins Scientific, Janoshik Analytical), not from the supplier’s own internal QA.
- Batch-level traceability. The lot number on the bottle label should map to a specific COA document. If batches share a single COA, that is a red flag.
- Clear formulation disclosure. Capsule strength (mcg per capsule), number of capsules per bottle, coating polymer, excipients. “Proprietary blend” labeling is not appropriate for research-grade material.
- For-research-only labeling. The product page, label, packing slip, and any customer-facing communication should all carry the research-only disclaimer. This is a regulatory baseline, not a marketing line.
- Documented supply chain. Where is the peptide synthesized? Who coats and fills the capsule? A supplier unable to answer these questions cannot guarantee reproducibility across batches.
- Sensible storage specification. Enteric-coated capsules of BPC-157 are typically specified for storage at 15–25 °C in a dry environment, with light protection. Specifications requiring refrigeration for a room-temperature-stable dosage form suggest a formulation issue.
4. How our Oral BPC-157 Capsules are specified
CertaPeptides supplies Oral BPC-157 Capsules at 500 mcg per capsule, enteric-coated, in sealed bottles. Each batch is released only after independent third-party analysis for:
- HPLC Purity Assay per USP <621> (specification: ≥98%)
- HPLC Potency Assay
- ESI-MS Identity Confirmation
- Endotoxin, USP <85> (specification: <0.5 EU/mg)
- Bioburden, USP <61>
COAs are issued by one of Analytical Sciences International, Eurofins Scientific, or Janoshik Analytical and delivered with the product at order confirmation. Lot numbers are printed on each bottle label and are traceable back to the specific analytical report for that batch.
Shipping across the European Union plus United Kingdom, Switzerland, and Norway is standard (3–7 business days via SameDay, FanCourier, or TCE Worldwide). Capsules ship at ambient temperature.
5. What this product is not
This product is supplied for in vitro and ex vivo research use only. It is not a medicine, food supplement, nutraceutical, or diagnostic product. It is not for human consumption, therapeutic use, or diagnostic procedures, and we do not provide dosing guidance for any human or veterinary application. Researchers evaluating BPC-157 in any context are expected to operate under their own institutional framework — ethics approval, biosafety, and applicable national regulations.
6. Related research standards
Common companion products for BPC-157 research workflows include:
- BPC-157 5mg lyophilized (injectable research form) — paired for oral vs. parenteral comparative designs
- TB-500 (Thymosin β-4 fragment) 5mg — frequently co-studied in tissue-regeneration models
- Bacteriostatic water 30mL — required for reconstitution of lyophilized comparator
- Thymosin Alpha-1 5mg — immunomodulatory peptide frequently used in parallel research stacks
FAQ
What is the difference between oral and injectable BPC-157 for research purposes?
Injectable (subcutaneous or intraperitoneal) delivery bypasses the gastrointestinal tract and gives direct systemic exposure. Oral enteric-coated capsules deliver the peptide to the small intestine and are used for intestinal-tissue-focused research, oral bioavailability characterization, and comparative pharmacokinetics.
Does enteric coating guarantee intact peptide release?
No. Enteric coating defers gastric degradation but does not prevent intestinal proteases from acting on the peptide after release. This is itself one of the reasons oral BPC-157 bioavailability is an active research question rather than a settled one.
Is a Certificate of Analysis required for research use?
Yes — any peptide used in research should be accompanied by batch-level analytical documentation from an independent laboratory. Internally generated QA sheets do not substitute for a third-party COA.
Can I combine oral BPC-157 research with injectable BPC-157 research?
Comparative designs pairing oral and parenteral forms of the same peptide are a standard tool for separating formulation effects from intrinsic peptide properties. Our oral and injectable BPC-157 products use peptide from the same synthesis specification, making this design straightforward.